Does the media refer more to FBIO or PSTV?

In the previous week, Fortress Biotech had 3 more articles in the media than Plus Therapeutics. MarketBeat recorded 4 mentions for Fortress Biotech and 1 mentions for Plus Therapeutics. Fortress Biotech's average media sentiment score of 0.00 equaled Plus Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortress Biotech 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Plus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ICCC or PSTV?

Plus Therapeutics has a consensus price target of $56.40, indicating a potential upside of 1,372.58%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Plus Therapeutics is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Plus Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43

Is ICCC or PSTV more profitable?

ImmuCell has a net margin of -1.82% compared to Plus Therapeutics' net margin of -230.24%. ImmuCell's return on equity of -1.88% beat Plus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets ImmuCell -1.82% -1.88% -1.22% Plus Therapeutics -230.24% -198.48% -73.13%

Does the media refer more to ICCC or PSTV?

In the previous week, ImmuCell had 3 more articles in the media than Plus Therapeutics. MarketBeat recorded 4 mentions for ImmuCell and 1 mentions for Plus Therapeutics. ImmuCell's average media sentiment score of 0.00 equaled Plus Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmuCell 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Plus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate PSTV or RFL?

Plus Therapeutics currently has a consensus price target of $56.40, suggesting a potential upside of 1,372.58%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Plus Therapeutics is more favorable than Rafael. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Plus Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PSTV or RFL more profitable?

Plus Therapeutics has a net margin of -230.24% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat Plus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Plus Therapeutics -230.24% -198.48% -73.13% Rafael -3,321.74% -41.27% -35.32%

Do analysts recommend CPIX or PSTV?

Plus Therapeutics has a consensus price target of $56.40, indicating a potential upside of 1,372.58%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Plus Therapeutics is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Plus Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43

Does the media refer more to CPIX or PSTV?

In the previous week, Cumberland Pharmaceuticals had 4 more articles in the media than Plus Therapeutics. MarketBeat recorded 5 mentions for Cumberland Pharmaceuticals and 1 mentions for Plus Therapeutics. Plus Therapeutics' average media sentiment score of 0.00 beat Cumberland Pharmaceuticals' score of -0.78 indicating that Plus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cumberland Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Negative Plus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PSTV or HRTX?

In the previous week, Heron Therapeutics had 8 more articles in the media than Plus Therapeutics. MarketBeat recorded 9 mentions for Heron Therapeutics and 1 mentions for Plus Therapeutics. Heron Therapeutics' average media sentiment score of 0.78 beat Plus Therapeutics' score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Plus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Heron Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Plus Therapeutics (PSTV) Competitors

$3.83 -0.03 (-0.78%)

As of 08/7/2026

Compare

PSTV vs. FBIO, ICCC, RFL, CPIX, and HRTX

Should you buy Plus Therapeutics stock or one of its competitors? Plus Therapeutics's main competitors and comparable companies include Fortress Biotech (FBIO), ImmuCell (ICCC), Rafael (RFL), Cumberland Pharmaceuticals (CPIX), and Heron Therapeutics (HRTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Plus Therapeutics compare to Fortress Biotech?

Fortress Biotech (NASDAQ:FBIO) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are held by institutional investors. 28.5% of Fortress Biotech shares are held by insiders. Comparatively, 2.5% of Plus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Fortress Biotech currently has a consensus target price of $17.00, suggesting a potential upside of 518.18%. Plus Therapeutics has a consensus target price of $56.40, suggesting a potential upside of 1,372.58%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Plus Therapeutics is more favorable than Fortress Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Fortress Biotech has higher revenue and earnings than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.44	$6.82M	$3.17	0.87
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A

Fortress Biotech has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

Fortress Biotech has a net margin of 193.12% compared to Plus Therapeutics' net margin of -230.24%. Fortress Biotech's return on equity of 109.66% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	193.12%	109.66%	45.56%
Plus Therapeutics	-230.24%	-198.48%	-73.13%

In the previous week, Fortress Biotech had 3 more articles in the media than Plus Therapeutics. MarketBeat recorded 4 mentions for Fortress Biotech and 1 mentions for Plus Therapeutics. Fortress Biotech's average media sentiment score of 0.00 equaled Plus Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Plus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Fortress Biotech beats Plus Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Plus Therapeutics compare to ImmuCell?

ImmuCell (NASDAQ:ICCC) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

Plus Therapeutics has a consensus price target of $56.40, indicating a potential upside of 1,372.58%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Plus Therapeutics is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

13.5% of ImmuCell shares are held by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are held by institutional investors. 5.7% of ImmuCell shares are held by company insiders. Comparatively, 2.5% of Plus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

ImmuCell has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market.

ImmuCell has higher revenue and earnings than Plus Therapeutics. ImmuCell is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$27.64M	3.59	-$1.04M	-$0.06	N/A
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A

ImmuCell has a net margin of -1.82% compared to Plus Therapeutics' net margin of -230.24%. ImmuCell's return on equity of -1.88% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	-1.82%	-1.88%	-1.22%
Plus Therapeutics	-230.24%	-198.48%	-73.13%

In the previous week, ImmuCell had 3 more articles in the media than Plus Therapeutics. MarketBeat recorded 4 mentions for ImmuCell and 1 mentions for Plus Therapeutics. ImmuCell's average media sentiment score of 0.00 equaled Plus Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmuCell	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Plus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ImmuCell beats Plus Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Plus Therapeutics compare to Rafael?

Plus Therapeutics (NASDAQ:PSTV) and Rafael (NYSE:RFL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Plus Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Rafael has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market.

Plus Therapeutics has a net margin of -230.24% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
Rafael	-3,321.74%	-41.27%	-35.32%

In the previous week, Plus Therapeutics had 1 more articles in the media than Rafael. MarketBeat recorded 1 mentions for Plus Therapeutics and 0 mentions for Rafael. Plus Therapeutics' average media sentiment score of 0.00 equaled Rafael'saverage media sentiment score.

Company	Overall Sentiment
Plus Therapeutics	Neutral
Rafael	Neutral

Plus Therapeutics has higher earnings, but lower revenue than Rafael. Rafael is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A
Rafael	$920K	111.91	-$30.52M	-$0.68	N/A

3.3% of Plus Therapeutics shares are held by institutional investors. Comparatively, 11.3% of Rafael shares are held by institutional investors. 2.5% of Plus Therapeutics shares are held by company insiders. Comparatively, 32.9% of Rafael shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Plus Therapeutics currently has a consensus price target of $56.40, suggesting a potential upside of 1,372.58%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Plus Therapeutics is more favorable than Rafael.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Plus Therapeutics beats Rafael on 8 of the 14 factors compared between the two stocks.

How does Plus Therapeutics compare to Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

Plus Therapeutics has a consensus price target of $56.40, indicating a potential upside of 1,372.58%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Plus Therapeutics is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are owned by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are owned by company insiders. Comparatively, 2.5% of Plus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cumberland Pharmaceuticals has a beta of 0.08, meaning that its share price is 92% less volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

Cumberland Pharmaceuticals has a net margin of -34.40% compared to Plus Therapeutics' net margin of -230.24%. Cumberland Pharmaceuticals' return on equity of -26.77% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-34.40%	-26.77%	-8.97%
Plus Therapeutics	-230.24%	-198.48%	-73.13%

In the previous week, Cumberland Pharmaceuticals had 4 more articles in the media than Plus Therapeutics. MarketBeat recorded 5 mentions for Cumberland Pharmaceuticals and 1 mentions for Plus Therapeutics. Plus Therapeutics' average media sentiment score of 0.00 beat Cumberland Pharmaceuticals' score of -0.78 indicating that Plus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cumberland Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Negative
Plus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cumberland Pharmaceuticals has higher revenue and earnings than Plus Therapeutics. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$22.30M	5.23	-$2.84M	-$0.71	N/A
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A

Summary

Cumberland Pharmaceuticals beats Plus Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Plus Therapeutics compare to Heron Therapeutics?

Plus Therapeutics (NASDAQ:PSTV) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Plus Therapeutics has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market.

Heron Therapeutics has higher revenue and earnings than Plus Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A
Heron Therapeutics	$150.71M	0.42	-$20.19M	-$0.18	N/A

3.3% of Plus Therapeutics shares are owned by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are owned by institutional investors. 2.5% of Plus Therapeutics shares are owned by company insiders. Comparatively, 6.1% of Heron Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Heron Therapeutics had 8 more articles in the media than Plus Therapeutics. MarketBeat recorded 9 mentions for Heron Therapeutics and 1 mentions for Plus Therapeutics. Heron Therapeutics' average media sentiment score of 0.78 beat Plus Therapeutics' score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Plus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Heron Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Heron Therapeutics has a net margin of -20.53% compared to Plus Therapeutics' net margin of -230.24%. Plus Therapeutics' return on equity of -198.48% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-230.24%	-198.48%	-73.13%
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%

Plus Therapeutics currently has a consensus target price of $56.40, indicating a potential upside of 1,372.58%. Heron Therapeutics has a consensus target price of $2.00, indicating a potential upside of 497.01%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Plus Therapeutics is more favorable than Heron Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Heron Therapeutics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Heron Therapeutics beats Plus Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Plus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PSTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PSTV vs. The Competition

Export

Metric	Plus Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$26.37M	$11.95B	$7.06B	$12.95B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	-1.67	788.51	269.75	24.73
Price / Sales	N/A	967.70	652.34	108.63
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	5.32	10.33	11.27	6.42
Net Income	-$22.39M	$2.77B	$3.45B	$347.12M
7 Day Performance	-2.05%	2.04%	3.56%	2.48%
1 Month Performance	-4.25%	-1.57%	-0.58%	-1.04%
1 Year Performance	-80.73%	191.33%	77.52%	23.22%

Plus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PSTV Plus Therapeutics	1.7936 of 5 stars	$3.83 -0.8%	$56.40 +1,372.6%	-80.7%	$26.37M	N/A	N/A	20	Upcoming Earnings Gap Down
FBIO Fortress Biotech	2.0214 of 5 stars	$2.76 -11.8%	$17.00 +515.9%	+46.7%	$103.98M	$63.26M	0.87	170	Upcoming Earnings High Trading Volume
ICCC ImmuCell	0.8997 of 5 stars	$11.04 -1.5%	N/A	+65.2%	$101.42M	$27.64M	N/A	70	Upcoming Earnings
RFL Rafael	0.2642 of 5 stars	$2.00 +3.3%	N/A	+26.7%	$100.88M	$920K	N/A	20	Gap Up
CPIX Cumberland Pharmaceuticals	0.3752 of 5 stars	$7.18 +7.5%	N/A	+141.5%	$100.09M	$41.94M	N/A	80	Earnings Report High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PSTV) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Plus Therapeutics (PSTV) Competitors

PSTV vs. FBIO, ICCC, RFL, CPIX, and HRTX

How does Plus Therapeutics compare to Fortress Biotech?

Summary

How does Plus Therapeutics compare to ImmuCell?

Summary

How does Plus Therapeutics compare to Rafael?

Summary

How does Plus Therapeutics compare to Cumberland Pharmaceuticals?

Summary

How does Plus Therapeutics compare to Heron Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSTV vs. The Competition

Plus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Plus Therapeutics (PSTV) Competitors

PSTV vs. FBIO, ICCC, RFL, CPIX, and HRTX

How does Plus Therapeutics compare to Fortress Biotech?

Do institutionals & insiders believe in FBIO or PSTV?

Do analysts prefer FBIO or PSTV?

Which has stronger earnings and valuation, FBIO or PSTV?

Which has more volatility & risk, FBIO or PSTV?

Is FBIO or PSTV more profitable?

Does the media refer more to FBIO or PSTV?

Summary

How does Plus Therapeutics compare to ImmuCell?

Do analysts prefer ICCC or PSTV?

Do insiders & institutionals believe in ICCC or PSTV?

Which has more risk and volatility, ICCC or PSTV?

Which has better valuation and earnings, ICCC or PSTV?

Is ICCC or PSTV more profitable?

Does the media refer more to ICCC or PSTV?

Summary

How does Plus Therapeutics compare to Rafael?

Which has more risk and volatility, PSTV or RFL?

Is PSTV or RFL more profitable?

Does the media prefer PSTV or RFL?

Which has preferable valuation & earnings, PSTV or RFL?

Do institutionals & insiders hold more shares of PSTV or RFL?

Do analysts rate PSTV or RFL?

Summary

How does Plus Therapeutics compare to Cumberland Pharmaceuticals?

Do analysts recommend CPIX or PSTV?

Do insiders and institutionals have more ownership in CPIX or PSTV?

Which has more volatility & risk, CPIX or PSTV?

Is CPIX or PSTV more profitable?

Does the media refer more to CPIX or PSTV?

Which has stronger valuation and earnings, CPIX or PSTV?

Summary

How does Plus Therapeutics compare to Heron Therapeutics?

Which has more volatility & risk, PSTV or HRTX?

Which has higher valuation & earnings, PSTV or HRTX?

Do insiders & institutionals believe in PSTV or HRTX?

Does the media prefer PSTV or HRTX?

Is PSTV or HRTX more profitable?

Do analysts rate PSTV or HRTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSTV vs. The Competition

Plus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools